AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04096274 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training and Technical Assistance Only
Description: All leaders and clinicians in participating clinics will receive standardized OQ-A training and technical assistance provided by the OQ-A purveyor organization. This includes an initial, 6-hr, in-person OQ-A training; two, live, virtual, 1-hr booster trainings, offered 3 and 5 months after the initial training; and, year-round technical assistance from the OQ-A purveyor organization. Technical assistance includes virtual training sessions, online library of training videos, and customer care representative for technical support.~In addition, to encourage participation in the study, a set of four 1-hr, web-based general leadership seminars will be offered to leaders in the control condition. These will cover topics ranging from effective leadership, to giving effective feedback.
Study NCT00705211 — intervention group
Intervention type: DRUG
Intervention: Ezetimibe
Description: Ezetimibe, 10-mg tablets,
Study NCT00705211 — intervention group
Intervention type: DRUG
Intervention: Ezetimibe + other lipid-lowering medication(s)
Description: Ezetimibe, 10-mg tablets, other lipid-lowering medication(s) as prescribed by attending physician
Study NCT00187421 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indocyanine green intraoperative angiogram and transit-time flowmetry
Description: ICG graft angiography following each distal anastomosis, and imaging of proximal anastomoses after all grafts completed.~transit time flowmetry performed on all grafts after all grafts completed.
Study NCT02204150 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OFDI Capsule
Description: Imaging of the esophagus using the OFDI Capsule and system
Study NCT00515801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glibenclamide
Description: glibenclamide 15 mg single dose
Study NCT00515801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsules, single dose
Study NCT03574090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin Clavulanate
Description: To demonstrate its efficacy in the prophylaxis of infection to surgical wound will be used in dirty/contaminated emergency surgery and its efficacy will be compared with topical administration of physiological serum alone.
Study NCT03574090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physiological Saline
Description: To demonstrate its efficacy in the prophylaxis of infection to surgical wound will be used in dirty/contaminated emergency surgery and its efficacy will be compared with topical administration of physiological serum alone.
Study NCT03574090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physiological Saline
Description: To demonstrate its efficacy in the prophylaxis of infection to surgical wound will be used in dirty/contaminated emergency surgery and its efficacy will be compared with topical administration of physiological serum alone.
Study NCT01208350 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: Monthly weigh-ins for 6 months without financial incentives associated with weight loss, and follow-up weigh-in at 9 months
Study NCT01208350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based payout
Description: Monthly weigh-ins for 6 months where five sequential participants, randomized to this condition, will be joined into virtual groups where individual rewards for weight loss are dependent on the weight loss of others in the group, with follow-up weigh in at 9 months
Study NCT01208350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual payout
Description: Monthly weigh-ins for 6 months and if monthly goals are met, participants receive payout at the end of the month, with follow-up weigh-in at 9 months
Study NCT00119535 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Implementation of Proactive Diabetes Eye Care Program
Study NCT02366611 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: tDCS is a non-invasive brain neuromodulatory method that involves sending a weak electrical current to the brain. 2mA of tDCS will be applied for 20 minutes at each session and participants will undergo a total of 20 sessions over a 7-week period.
Study NCT01050309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hexaminolevulinate (HAL)
Description: Intravenous dose of HAL 0.4 mg/kg including 100 nCi (3.7 kBq) 14C infused over a one hour period. A vaginal dose HAL 150 mg including 13,9 kBq of 14C HAL will be administered for 7 hours. Following a colon cleaning, 100mg HAL enema including 14,8 kBq of 14C will be instilled for 30 minutes in colon
Study NCT02728193 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Study NCT02728193 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MWV
Study NCT02728193 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEI
Description: Percutaneous ethanol injection
Study NCT00985062 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mild Ovarian Stimulation Treatment
Description: Administration of a fixed dose of 150 IU/day rFSH s.c. (Puregon® NV Organon, Oss, The Netherlands) from cycle day 5 onwards. As soon as the leading follicle reached a diameter of 14mm, a GnRH-antagonist (Orgalutran®, NV Organon, Oss, The Netherlands) was administered at 0.25 mg/day s.c.. To induce final oocyte maturation a single s.c. dose of 10.000 IE hCG (Pregnyl®, NV Organon. Oss, The Netherlands) was administered.
Study NCT00985062 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Ovarian Stimulation Treatment
Description: Administration of GnRH agonist Triptorelin (Decapeptyl®, Ferring BV, Hoofddorp, The Netherlands) at 0.1 mg/day s.c., starting on cycle day 21 of the menstrual cycle preceding the actual stimulation cycle. After two weeks of the GnRH regimen, co-treatment with rFSH 225 IU/day s.c. (Puregon®, NV Organon, Oss, The Netherlands) was initiated. To induce final oocyte maturation a single s.c. dose of 10.000 IE hCG (Pregnyl®, NV Organon. Oss, The Netherlands) was administered
Study NCT03746704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr˗DFO˗REGN3504
Description: 89Zr˗DFO˗REGN3504
Study NCT02146612 — intervention group
Intervention type: OTHER
Intervention: Amino Acid Supplement Group
Description: Group receiving nutritional supplement
Study NCT04438473 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pectin-supplemented enteral nutrition feeding
Description: sequential supplementation with combination of 90ml pectin and 500ml enteral nutrition formula for 7 days
Study NCT04438473 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: enteral nutrition feeding
Description: standard formula enteral nutrition feeding without pectin for 7 days
Study NCT00290615 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study NCT00290615 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Study NCT00290615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT00290615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study NCT02222207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib, ophthalmic oily suspension (BAY73-4506)
Description: Subjects receive Regorafenib as eye drops
Study NCT02222207 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham IVT
Description: Sham injections
Study NCT02222207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Subjects receive Ranibizumab as intravitreal injection
Study NCT02222207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo eye drops
Study NCT01696513 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcision
Study NCT01696513 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subcision
Study NCT02300298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib
Study NCT02300298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel
Study NCT04314921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga trainings
Description: 10-week yoga sessions, 2 times per week, 90 min per session.
Study NCT01982292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLX030 (serelaxin)
Description: RLX030 (serelaxin) was administered according to a weight-range adjusted dosing regimen at a nominal dose of 30 μg/kg/day as a continuous IV infusion for 48 hours.
Study NCT01982292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo of serelaxin was administered as a continuous IV infusion for 48 hours.
Study NCT03258528 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: positioning
Description: Positioning neonates for 6 hours either in right lateral position or supine position
Study NCT02586675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Tamoxifen will be taken orally once daily on a continuous daily schedule (e.g., days 1-28 of each 28 day cycle).
Study NCT02586675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib (LEE011) will be taken orally once daily on days 1-21 of each 28 day cycle. Days 22-28 will be a rest period from dosing with Ribociclib. In the continuous cohort, 400 mg ribociclib will be given daily (QD).
Study NCT02586675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Goserelin will be given as an injectable subcutaneous implant on day 1 of every 28 day cycle. This will be given in pre-menopausal and peri-menopausal women.
Study NCT04500977 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: leadership empowerment
Description: In the leadership program, women were taught more about the manner in which to bring about a change in one's health by adapting a healthy life style, leadership and facilitation skills and the development, implementation and evaluation process required to conduct a community program that will impact society. Women learned how to map needs and resources, define goals and objectives, develop, implement and evaluate a community based program.
Study NCT03108313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aloe vera toothpaste
Description: herbal toothpaste used to decrease salivary streptococcus bacterial count
Study NCT04950478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: 5 minutes before the procedure, they were recorded on 'Child and Parent Information Form', State-Trait Anxiety Inventory for Children and FPS-R. Their heart rate and oxygen saturation values were read and recorded. Children wore the virtual reality headset and game was started one minute before the venipuncture. As soon as the injector inserted, the researcher turned on a stopwatch and read and recorded heart rate and oxygen saturation values. When the injector was removed, the researcher stopped the stopwatch and recorded the duration of the procedure.When the injector was removed, the stopwatch was stopped and heart rate and oxygen saturation were recorded. The children took off the virtual reality headset and were asked to evaluate their pain level through FPS-R and their responses were recorded.
Study NCT03743935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced cardiac MRI
Description: Gadolinium-enhanced cardiac MRI during the 1st days post-STEMI with specific sequences including extra-cellular volume measurement
Study NCT00329524 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: TMS will initially be targeted to asymmetric cortical activation in one hemisphere, as defined by PET-CT imaging. TMS will then be optimized by identifying the area of maximal tinnitus suppression, within the area of asymmetry, by delivering single 1-Hz pulses of TMS at the MT. The area of maximal tinnitus suppression, as reported by the patient, will then be targeted for treatment with rTMS at 1-Hz frequency, delivering 1800 pulses at 110% MT on each of 5 consecutive treatment days.If no area of maximal tinnitus suppression can be found in the hemisphere initially targeted for treatment based on PET, we will perform the optimization procedure in a homologous region of the opposite cerebral hemisphere to determine if a maximal area of suppression can be found there. Each group will then crossover to sham and active stimulation conditions, respectively, 7 days following the completion of the first treatment session.
Study NCT04504409 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Training
Study NCT04504409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Training
Study NCT00795119 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near Infrared Spectroscopy (NIRS)
Description: NIRS of the head is undertaken at the time of CT or MRI examination
Study NCT03108313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoride toothpaste
Description: chemical toothpaste used to decrease salivary streptococcus bacterial count
Study NCT01628185 — intervention group
Intervention type: PROCEDURE
Intervention: Repositioning
Description: pain assessment at baseline then following routine care repositioning in bed
Study NCT03593616 — intervention group
Intervention type: PROCEDURE
Intervention: Phacoemulsification
Description: insertion of intra-ocular lens after emulsification of catractous lens
Study NCT02681354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biorescue training
Study NCT04064216 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic surgery
Description: Patients that will undergo robot assisted laparoscopic surgery and conventional laparoscopic surgery for benign gynecologic disorders will answer 4 questionnaires to assess patient satisfaction, quality of life and cosmesis
Study NCT04570553 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical staging
Description: Patients will undergo standard surgical staging for endometrial cancer utilizing either a V-care uterine manipulator or sponge stick
Study NCT03698591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation task
Description: Experimenters will employ a continuous theta-burst stimulation (cTBS) sequence using a figure-8 coil positioned tangentially to the scalp over the target coordinates. Experimenters have defined the target coordinates for stimulation (Montreal Neuroscience Institute coordinates -53, -53, 23) based on peak objective distancing activation in the left temporal parietal junction (TPJ) in previous fMRI studies using the same task.
Study NCT04570553 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical staging
Description: Patients will undergo standard surgical staging for endometrial cancer utilizing either a V-care uterine manipulator or sponge stick
Study NCT03698591 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial magnetic stimulation task
Description: A sham version of the TMS intervention where subjects will receive a small electrical stimulation on the scalp via two small electrodes in conjunction with a TMS coil activation. The TMS coil will be reoriented to stimulate into the air away from the scalp, simulating traditional TMS, without inducing any current to the subject.
Study NCT02714322 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MYL-1401A (Adalimumab)
Description: MYL-1401A initial dose of 80 mg administered subcutaneously (sc), followed by 40 mg sc given every other week starting 1 week after the initial dose
Study NCT02714322 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Humira® (Adalimumab)
Description: Humira® initial dose of 80 mg administered sc, followed by 40 mg sc given every other week starting 1 week after the initial dose
Study NCT02369172 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bupropion
Study NCT02369172 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ASP2151
Study NCT01011309 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LEISH-F2 + MPL-SE
Description: 10 μg LEISH-F2 + 25 μg MPL-SE on Days 0, 28 and 56
Study NCT01011309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium stibogluconate
Description: 20 mg/kg/day IV daily for 20 days
Study NCT01750749 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous BMDC implantation at the venous ulcer
Description: An autologous bone marrow derived cell concentrate is obtained by bone marrow harvest (300 ml) from the iliac crest and subsequent processing using 6% hydroxyethyl starch to concentrate nucleated cells. The cells are injected using a 27 Gauge needle, in aliquots of 0.2 ml, along the venous ulcer edge. SOC treatment consisting of advanced wound management plus pressure therapy is administered simultaneously.
Study NCT03858816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixture probiotics
Description: The mixture probiotics capsule
Study NCT03858816 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo contains the same excipient ingredients but without the live bacteria.
Study NCT03807375 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CPAP preoxygenation
Description: During preoxygenation, the ventilator device will be placed in spontaneous mode and set as CPAP: 5 cmH2O.
Study NCT03175666 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: avelumab
Description: Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
Study NCT03175666 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Recombinant human anti-VEGF IgG1 monoclonal antibody
Study NCT03175666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Study NCT00495898 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CYPHER sirolimus-eluting stent
Description: drug-eluting stent
Study NCT00495898 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: uncoated Bx VELOCITY balloon-expandable stent
Description: bare metal stent
Study NCT03175666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: (SP-4-2)-diamminedichloroplatinum(II)
Study NCT03175666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Study NCT03175666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione
Study NCT03175666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
Study NCT03175666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: 5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
Study NCT03175666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza
Description: omega-3-acid ethyl esters)
Study NCT03175666 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: (SBRT)
Study NCT03175666 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: recombinant human super agonist interleukin-15 (IL-15) complex
Study NCT03175666 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-011
Description: adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-CEA (carcinoembryonic antigen)
Study NCT00610480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1st visit Optive, then 2nd visit Systane
Description: First visit: Instillation of Optive followed by evaporometry assessment after 30 minutes.~Second visit: Instillation of Systane followed by evaporometry assessment after 30 minutes.
Study NCT03175666 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-051
Description: Ad5 \[E1-, E2b-\]-Brachyury
Study NCT03175666 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-061
Description: Ad5 \[E1-, E2b-\]-mucin 1 (MUC1)
Study NCT03175666 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-4000
Description: RAS yeast vaccine
Study NCT03175666 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6207
Description: CEA yeast vaccine
Study NCT00610480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1st visit Systane, then 2nd visit Optive
Description: First visit: Instillation of Systane followed by evaporometry assessment after 30 minutes.~Second visit: Instillation of Optive followed by evaporometry assessment after 30 minutes.
Study NCT04326426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tradipitant
Description: Neurokinin-1 antagonist
Study NCT04326426 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT03801044 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: NT-BNP, VEGF
Description: VEGF-C levels were measured in the serum samples. R\&D Systems kit (Minneapolis, MN) (Catalog Number DVEC00) was used for the assays according to the user instructions. NT-proBNP was measured on the Elecsys 2010 analyzer (Elecsys proBNP Immunoassay; Roche Diagnostics).